. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003 Oct;17(13):1945-7. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on Primary Papers and News

  1. These two exciting articles provide significant momentum for the field of Parkinson's disease research. The Singleton/Farrer paper cements the role of α-synuclein as a central player in the pathogenesis of PD. Their discovery of an elevated gene dosage effect of the snca gene in the Iowa kindred bears obvious resemblance to the elevated gene dosage of the APP gene conferred by trisomy 21 and its role in the pathogenesis of Alzheimer's disease.

    Omar el Agnaf's work raises many intriguing questions. One, whether α-synuclein levels in body fluids of humans may be used as a biomarker for the disease, and two, as to the precise source of α-synuclein in peripheral blood, which may be platelets. In that sense, el-Agnaf's work also shows intriguing parallels to Alzheimer's disease, as APP isoforms, including of amyloid β-protein, have been found in peripheral blood and CSF. These findings are also of possible relevance to multiple system atrophy, a PD-like illness in which α-synuclein deposits are predominantly found in oligodendroglia, a type of cell that usually does not express significant amounts of the snca gene product.

    View all comments by Michael Schlossmacher

This paper appears in the following:

News

  1. Synuclein and Parkinson's—It's All in the Dose